Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS／Cervarix Wins Tender for UK National Immunization Program: GSK
August 4, 2008
- Alizyme Licenses COLAL-PRED to Norgine in Europe
August 4, 2008
- BMS, AZ Apply for Saxagliptin in Europe
August 4, 2008
- BUSINESS NEWS IN BRIEF
August 4, 2008
- Primovist Approved in the US: Bayer HealthCare
August 4, 2008
- TOPICS／JADEC, sanofi-aventis Cosponsor HbA1c Awareness Enhancement Campaign
August 4, 2008
- PMDA Receives Highest Rating Regarding Balance of Payment, Relief of ADR Victims
August 4, 2008
- NEW PRODUCTS／Aroglycem Cap. for Hypoglycemia due to Hyperinsulinemia: Schering-Plough
August 4, 2008
- OPINION／Who Makes \30 Million? Our Survey Reveals All
August 4, 2008
- Irinotecan to See First Generics in November
August 4, 2008
- Kobayashi Launches 7 New Products
August 4, 2008
- Councils for Promotion of Use of Generics Created by 30 Prefectures
August 4, 2008
- Paltac KS to Report Profits This Fiscal Year
August 4, 2008
- More Doctors Concerned about Quality of Generics Based on Their Own Experience
August 4, 2008
- Miconazole, Emedastine Fumarate Classified into Class 1 OTC Drugs
August 4, 2008
- GENERICS NEWS IN BRIEF
August 4, 2008
- Updating Reduces Number of Class 1 OTC Drugs from 23 to 21
August 4, 2008
- Fuji Yakuhin Developing Drug for Gout at PII
August 4, 2008
- SELF-MEDICATION NEWS IN BRIEF
August 4, 2008
- Novartis to Apply for Everolimus for RCC within 2008
August 4, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…